3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Endocrine
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Skin Neoplasms
7
Neoplasm Metastasis
6
Squamous Cell Carcinoma of Head and Neck
5
Melanoma
5
Lung Neoplasms
5
Carcinoma
5
Recurrence
4
Neoplasms
4
Colorectal Neoplasms
4
Mouth Neoplasms
3
Glioblastoma
3
Colonic Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Adenocarcinoma
3
Ovarian Neoplasms
2
Mycosis Fungoides
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, B-Cell
2
Laryngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Basal Cell
2
Vaccinia
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Interventions
tremelimumab
2
pembrolizumab
2
Nivolumab
2
Carboplatin
2
poly ICLC
1
osimertinib
1
lenvatinib
1
durvalumab
1
cemiplimab
1
balstilimab
1
Vascular Endothelial Growth Factor A
1
Peptides
1
Pemetrexed
1
Paclitaxel
1
Ipilimumab
1
Docetaxel
1
Blood Specimen Collection
1
Antibodies, Bispecific
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
cemiplimab
×
90 days
×
Clear all
NCT05142189
2026-04-14
LuCa-MERIT-1
BioNTech SE
Phase 1
Recruiting
320 enrolled